文献速递类风湿关节炎系统性红斑狼疮其他结缔组织病

慢性炎症性与自身免疫性风湿病患者中医院PCR确诊COVID-19的患病率

Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases.
PubMed 文献 · Ann Rheum Dis · 2020-06-12

西班牙七家医院回顾性研究将风湿病患者数据库与医院SARS-CoV-2 PCR阳性检测匹配,发现慢性炎症性疾病患者医院PCR确诊COVID-19患病率为0.76%,高于参考人群的0.58%(1.32倍)。系统性自身免疫或免疫介导疾病患者显著增加,而炎症性关节炎或系统性红斑狼疮患者未显著增加。部分诊断组COVID-19病例年龄大于参考人群,炎症性关节炎患者使用靶向合成或生物DMARDs者患病率更高。

要点

  • 慢性炎症性疾病患者医院PCR确诊COVID-19患病率为0.76%,参考人群为0.58%。
  • 系统性自身免疫或免疫介导疾病患者COVID-19患病率显著增加。
  • 炎症性关节炎患者使用靶向合成或生物DMARDs者患病率更高,而传统合成DMARDs者未增高。

核心结论

  • 系统性自身免疫或免疫介导疾病患者医院诊断COVID-19的风险存在差异,衰老、治疗和疾病特异性因素的相互作用可能起作用。

研究设计与样本

  • 西班牙七家医院风湿科随访患者的回顾性研究,将风湿病患者数据库与医院SARS-CoV-2阳性PCR检测的参考人群进行匹配。

主要发现

  • 慢性炎症性疾病患者医院PCR确诊COVID-19患病率为0.76%,参考人群为0.58%,为1.32倍。
  • 系统性自身免疫或免疫介导疾病患者患病率显著增加,而炎症性关节炎或系统性红斑狼疮患者未显著增加。
  • 部分诊断组COVID-19病例年龄大于参考人群。
  • 炎症性关节炎患者使用靶向合成或生物DMARDs者患病率更高,而使用传统合成DMARDs者未增高。

临床怎么用

  • 这些数据为改进风湿病患者预防建议及分析COVID-19易感性相关特定因素提供基础。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The susceptibility of patients with rheumatic diseases and the risks or benefits of immunosuppressive therapies for COVID-19 are unknown. METHODS: We performed a retrospective study with patients under follow-up in rheumatology departments from seven hospitals in Spain. We matched updated databases of rheumatology patients with severe acute respiratory syndrome coronavirus 2-positive PCR tests performed in the hospital to the same reference populations. Rates of PCR+ confirmed COVID-19 were compared among groups. RESULTS: Patients with chronic inflammatory diseases had 1.32-fold higher prevalence of hospital PCR+ COVID-19 than the reference population (0.76% vs 0.58%). Patients with systemic autoimmune or immune-mediated disease (AI/IMID) showed a significant increase, whereas patients with inflammatory arthritis (IA) or systemic lupus erythematosus did not. COVID-19 cases in some but not all diagnostic groups had older ages than cases in the reference population. Patients with IA on targeted-synthetic or biological disease-modifying antirheumatic drugs (DMARDs), but not those on conventional-synthetic DMARDs, had a greater prevalence despite a similar age distribution. CONCLUSION: Patients with AI/IMID show a variable risk of hospital-diagnosed COVID-19. Interplay of ageing, therapies and disease-specific factors seem to contribute. These data provide a basis to improve preventive recommendations to rheumatic patients and to analyse the specific factors involved in COVID-19 susceptibility.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Pablos JL, Abasolo L, Alvaro-Gracia JM, et al. Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. Ann Rheum Dis. 2020. PMID: 32532753. doi:10.1136/annrheumdis-2020-217763

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。